APPLICATION OF THIOTRIAZOLINE IN COMBINATION WITH EXTRACORPORAL HEMOCORRECTION IN PATIENTS WITH ACUTE PULMONARY SUPPRESSIONS IN LATE PERIOD OF TRAUMATIC DISEASE
DOI:
https://doi.org/10.31379/2411.2616.17.1.4Keywords:
traumatic disease, thiotriazoline, pulmonary suppurationAbstract
A comparative analysis of the results of a comprehensive examination and treatment of 28 patients with severe forms of acute infectious destruction of the lungs in the late period (TB) was carried out. 62.5% of patients were people of the most working age – from 20 to 50 years. They were mostly men – 80.5%. In addition to drainage, sanitation of purulent cavities and traditional conservative therapy, these patients used extracorporeal hemocorrection methods to relieve progressive endotoxicosis. In patients receiving thiotriazoline (in pre-perfusion preparation and as part of intensive treatment of the post-perfusion period), a more favorable course of the disease was noted (rapid positive dynamics of indicators of systemic inflammatory response, toxemia and oxygen homeostasis indicators, compared with patients receiving traditional therapy), which contributed to reduction of terms and improvement of the quality of treatment of patients. The revealed changes indicate the advisability of using thiotriavzoline as part of pre-perfusion preparation and the basic program of complex treatment in patients with acute infectious lung destruction in the late period of TD.
References
Global Cancer Statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. / F. Bray [et al.] // CA: a cancer journal for clinicians. – 2018. – Vol. 68(6). – P. 394–424.
Ohlsson-Nevo, E., Alkebro, I., Ahlgren, J. Cancer patients’ interest in participating in cancer rehabilitation. Acta Oncol. – 2019. – Vol. 58(12). – P. 1676–1683. doi: 10.1080/0284186X.2019.1633017.
Motivational interviewing added to oncology rehabilitation did not improve moderate-intensity physical activity in cancer survivors: a randomised trial. / A.M. Dennett [et al.] // J Physiother. – 2018. – Vol. 64(4). – P. 255–263. doi: 10.1016/j.jphys.2018.08.003.
Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing. / R. Ngoune [et al.] // Curr Drug Deliv. – 2018. – Vol. 15(9). – P. 1261–70. doi: 10.2 174/1567201815666180518125839.
Plasmapheresis, Intravenous Immunoglobulins, and Autologous Serum Eyedrops in the Acute Eye Complications of Toxic Epidermal Necrolysis. / A. Pinna [et al.] // Eur J Ophthalmol. – 2017. – Vol. 27(6). – P. 658–663. doi: 10.5301/ejo.5000923.
Hemostasis management and therapeutic plasma exchange: Results of a practice survey. / N.D. Zantek [et al.] // J Clin Apher. – 2018. – Vol. 33(5). – P. 604–610. doi: 10.1002/jca.21653.
Influence of virtual intervention and blood rheology on mass transfer through thoracic aortic aneurysm. / Y. Lei [et al.] //J Biomech. – 2015. – Vol. 48(12). – P. 3312–22. doi: 10.1016/j.jbiomech.2015.06.022.
Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: singlecenter results of stepwise escalation of immunosuppression. / A.A. de Joode [et al.] // J Clin Apher. – 2014. – Vol. 29(5). – P. 266–72. doi: 10.1002/jca.21318.
Extracorporeal membrane oxygenation-hemostatic complications. / D.A. Murphy [et al.] //Transfus Med Rev. – 2015. – Vol. 29(2). – P. 90–101. doi: 10.1016/j.tmrv.2014.12.001.
Effects of double filtration plasmapheresis on nocturnal respiratory function in myasthenic patients. / J.H. Yeh [et al.] // Artif Organs. – 2013. – Vol. 37(12). – P. 1076–9. doi: 10.1111/aor.12128.
Case of Alport Syndrome with Posttransplant Antiglomerular Basement Membrane Disease despite Negative Antiglomerular Basement Membrane Antibodies by EIA Treated with Plasmapheresis and Intravenous Immunoglobulin. / S.I. Armstead [et al.] // Case Rep Transplant. – 2013. – P. 164016. doi: 10.1155/2013/164016.
Circulating tumor DNA: new horizons for improving cancer treatment. / G.D. Lianos [et al.] //Future Oncol. – 2015. – Vol. 11(4). – P. 545–8.
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. / M. Murtaza [et al.] // Nature. – 2013. – Vol. 497(7447). – P. 108–12. doi: 10.1038/nature12065.
